The new medical innovations:
Anktiva for Bladder Cancer: FDA Approved Immunotherapy That Avoids Chemotherapy
Anktiva (nogapendekin alfa inbakicept-pmln) is an FDA approved immunotherapy used with BCG for adults with BCG unresponsive non muscle invasive bladder cancer with carcinoma in situ (with or without papillary tumors). Instead of chemotherapy, this therapy is designed to activate the immune system, including natural killer cells, to help recognize and destroy cancer cells in the bladder.